Get the Stockscreener App
9.20
0.11%
-0.01
Pre-market:
9.21
0.01
+0.11%
Novavax Inc stock is traded at $9.20, with a volume of 4.14M.
It is down -0.11% in the last 24 hours and up +1.55% over the past month.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
See More
Previous Close:
$9.21
Open:
$9.22
24h Volume:
4.14M
Relative Volume:
0.92
Market Cap:
$1.51B
Revenue:
$596.34M
Net Income/Loss:
$-87.84M
P/E Ratio:
-15.40
EPS:
-0.5975
Net Cash Flow:
$-97.62M
1W Performance:
+6.11%
1M Performance:
+1.55%
6M Performance:
+40.67%
1Y Performance:
+30.87%
1-Day Range:
$8.95
$9.595
1-Week Range:
$8.45
$9.595
52-Week Range:
$6.13
$11.97
Novavax Inc Stock (NVAX) Company Profile
Name
Novavax Inc
Sector
Industry
Phone
240-268-2000
Address
21 FIRSTFIELD RD, GAITHERSBURG, MD
Compare NVAX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
9.20 | 1.51B | 596.34M | -87.84M | -97.62M | -0.5975 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Novavax Inc Stock (NVAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-24-25 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-28-25 | Resumed | H.C. Wainwright | Buy |
| Aug-20-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-17-25 | Initiated | Citigroup | Sell |
| Feb-28-25 | Initiated | BTIG Research | Buy |
| Jul-30-24 | Downgrade | JP Morgan | Neutral → Underweight |
| May-10-24 | Upgrade | BofA Securities | Underperform → Neutral |
| May-10-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-09-23 | Upgrade | B. Riley Securities | Neutral → Buy |
| Apr-20-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Mar-01-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-09-23 | Reiterated | B. Riley Securities | Buy |
| Dec-30-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-02-22 | Initiated | Jefferies | Hold |
| Sep-22-22 | Downgrade | JP Morgan | Neutral → Underweight |
| May-20-22 | Initiated | BofA Securities | Underperform |
| Feb-23-22 | Reiterated | B. Riley Securities | Buy |
| Feb-22-22 | Resumed | Jefferies | Buy |
| Jan-21-22 | Initiated | Cowen | Outperform |
| May-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-14-20 | Initiated | Jefferies | Buy |
| Aug-06-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-05-20 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
| Jul-16-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jun-29-20 | Reiterated | B. Riley FBR | Buy |
| Jun-29-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-05-20 | Upgrade | JP Morgan | Underweight → Neutral |
| May-28-20 | Reiterated | B. Riley FBR | Buy |
| May-12-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-27-19 | Resumed | B. Riley FBR | Buy |
| Aug-14-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-28-19 | Downgrade | Piper Jaffray | Overweight → Underweight |
| Dec-18-18 | Initiated | Ladenburg Thalmann | Buy |
| Dec-11-18 | Initiated | Oppenheimer | Outperform |
| Nov-26-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Sep-21-18 | Upgrade | JP Morgan | Underweight → Overweight |
| Mar-29-18 | Upgrade | Seaport Global Securities | Neutral → Buy |
View All
Novavax Inc Stock (NVAX) Latest News
Novavax Inc. stock outperforms competitors on strong trading day - MarketWatch
NVAX Stock Rises Overnight Ahead Of Q4 Print With Pfizer Tailwinds — Analyst Warns Of 20% Crash - Stocktwits
Novavax (NVAX) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo Finance Australia
Novavax Inc. stock underperforms Friday when compared to competitors - MarketWatch
Novavax Price Target Maintained With a $19.00/Share by BTIG - Moomoo
NVAX News | NOVAVAX INC (NASDAQ:NVAX) - ChartMill
Novavax Swings To Profit In Q4 Fueled By Nuvaxovid-Linked Revenue - Stocktwits
Novavax set for a seventh straight decline - MSN
Novavax Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
Novavax Stock Hits Over 1-Year High: Is Sanofi’s Flu-COVID Shot The Post-Pandemic Growth Driver? - Stocktwits
Novavax rises after six sessions of decline - MSN
Novavax Pivots To Matrix M Licensing As Sanofi Takes Europe - Yahoo Finance
Novavax Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Novavax (NVAX) Shares Decline Amid Transition to Royalty Model - GuruFocus
(NVAX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Novavax Q4 Earnings Preview: Wall Street Expects Wider Losses Amid Diversification Efforts - Stocktwits
Novavax Inc. stock underperforms Monday when compared to competitors - MarketWatch
Novavax (NVAX) up 10.4% since last earnings report: Can it continue? - MSN
Novavax, Inc. (NVAX) is attracting investor attention: Here is what you should know - MSN
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
NOVAVAX INC (NVAX) Stock Chart - ChartMill
NVAX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Novavax Q1 2026 slides: partnership revenue surges amid strategic shift - Investing.com
Earnings call transcript: Novavax Q1 2026 beats forecasts, stock surges - Investing.com
Novavax Inc stock (US6707721049): Q1 2026 results and valuation metrics in focus - AD HOC NEWS
Novavax, Inc. Trade Ideas — BSESOF:NVV1 - TradingView
Novavax (NVAX) Up 10.4% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Novavax beats first-quarter revenue estimates on strength in vaccine deals - marketscreener.com
Novo Nordisk opens Czech facility for obesity drugs - marketscreener.com
Novavax rises after strong Q1 beat driven by Pfizer deal - MSN
NVAX Technical Analysis | Trend, Signals & Chart Patterns | NOVAVAX INC (NASDAQ:NVAX) - ChartMill
Novavax Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Deadline in 2 Days: Kessler Topaz Meltzer & Check, LLP Reminds Novavax, Inc. (NVAX) Investors of Filing Deadline in Class Action Lawsuit and Encourages Investors with Substantial Losses to Contact the Firm - TMX Newsfile
Novavax to Participate in 2026 Jefferies Global Healthcare Confe - GuruFocus
Novavax to Participate in 2026 Jefferies Global Healthcare Conference - PR Newswire
Novavax Inc stock (US6707721049): Analyst consensus points to hold as NVAX trades near 11 USD - AD HOC NEWS
Novavax fireside chat at 2026 Jefferies Global Healthcare Conference - Stock Titan
Novavax Stock Soars 13.57%, Hits Intraday High of $10.52 - Markets Mojo
Novavax: The Pivot To A Royalty Model Is Working, But It's Still A Hold (NASDAQ:NVAX) - Seeking Alpha
Liquidity Mapping Around (NVAX) Price Events - Stock Traders Daily
Novavax Inc stock (US6707721049): shares trade around USD 10 after recent volatility and licensing f - AD HOC NEWS
Novavax Inc. stock underperforms Thursday when compared to competitors - MarketWatch
FDA advisers recommend COVID vaccines be updated to target current dominant variant - Reuters
Novavax Inc stock (US66987V1098): NVAX trades at $11.09 on Nasdaq - AD HOC NEWS
R. Draghia Akli sells 30,000 NVAX shares (NASDAQ: NVAX) - Stock Titan
Why Novavax (NVAX) Stock Is Trading Up Today - Yahoo Finance
Novavax Inc Stock (NVAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):